Analyst Marc Goodman from Leerink Partners maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) and keeping the price target at $220.00.
Marc Goodman has given his Buy rating due to a combination of factors that reflect both current challenges and future potential for Jazz Pharmaceuticals. Despite a messy first-quarter performance, marked by missed revenue expectations and various financial adjustments, Goodman remains optimistic about the company’s future. The focus is on the promising data expected from the Zani GEA study in the second half of 2025, which is anticipated to be a significant catalyst for the stock.
Additionally, Goodman acknowledges the steady growth in key products like Xywav and Epidiolex, which have shown year-over-year increases. Although there were some negative sales variances compared to estimates, the overall strategy and potential for future growth, particularly with upcoming catalysts, support the Buy rating. The adjustments in EPS forecasts also reflect a strategic realignment to better capture the company’s long-term growth prospects.
JAZZ’s price has also changed slightly for the past six months – from $111.550 to $111.170, which is a -0.34% drop .